1. Home
  2. NTRB vs BNTC Comparison

NTRB vs BNTC Comparison

Compare NTRB & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutriband Inc.

NTRB

Nutriband Inc.

HOLD

Current Price

$7.80

Market Cap

72.6M

Sector

Health Care

ML Signal

HOLD

Logo Benitec Biopharma Inc.

BNTC

Benitec Biopharma Inc.

HOLD

Current Price

$10.99

Market Cap

396.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRB
BNTC
Founded
2016
1995
Country
United States
United States
Employees
N/A
24
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.6M
396.3M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
NTRB
BNTC
Price
$7.80
$10.99
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$27.67
AVG Volume (30 Days)
67.4K
118.5K
Earning Date
05-29-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.67
EPS
N/A
N/A
Revenue
$2,036,651.00
N/A
Revenue This Year
$30.17
N/A
Revenue Next Year
$3,394.36
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.80
$9.85
52 Week High
$8.63
$16.76

Technical Indicators

Market Signals
Indicator
NTRB
BNTC
Relative Strength Index (RSI) 75.77 36.33
Support Level $4.18 $10.04
Resistance Level N/A $14.14
Average True Range (ATR) 0.64 0.65
MACD 0.16 -0.17
Stochastic Oscillator 90.70 9.25

Price Performance

Historical Comparison
NTRB
BNTC

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

About BNTC Benitec Biopharma Inc.

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.

Share on Social Networks: